Precision periodontics: Quantitative measures of disease progression

Robert Gellibolian; Craig S. Miller; Adam N. Markaryan; Robin L. Weltman; Thomas E. Van Dyke; Jeffrey L. Ebersole

doi:10.1016/j.adaj.2022.03.005

Precision periodontics: Quantitative measures of disease progression

Robert Gellibolian
, Craig S. Miller
, Adam N. Markaryan
, Robin L. Weltman
, Thomas E. Van Dyke
, Jeffrey L. Ebersole

Research output: Contribution to journal › Editorial

8 Scopus citations

Original language	English
Pages (from-to)	826-828
Number of pages	3
Journal	Journal of the American Dental Association
Volume	153
Issue number	9
DOIs	https://doi.org/10.1016/j.adaj.2022.03.005
State	Published - Sep 2022

Bibliographical note

Funding Information:
Disclosures. Drs. Gellibolian and Markaryan have shares in CellectGen, a for-profit organization focused on developing some of the point-of-care technologies proposed in this commentary. The work is funded by private investment capital. None of the other authors reported any disclosures.

Funding

Disclosures. Drs. Gellibolian and Markaryan have shares in CellectGen, a for-profit organization focused on developing some of the point-of-care technologies proposed in this commentary. The work is funded by private investment capital. None of the other authors reported any disclosures.

ASJC Scopus subject areas

General Dentistry

Access to Document

10.1016/j.adaj.2022.03.005

Cite this

@article{52c378d493c94c4ab6ab651fd9c21f57,

title = "Precision periodontics: Quantitative measures of disease progression",

author = "Robert Gellibolian and Miller, \{Craig S.\} and Markaryan, \{Adam N.\} and Weltman, \{Robin L.\} and \{Van Dyke\}, \{Thomas E.\} and Ebersole, \{Jeffrey L.\}",

note = "Funding Information: Disclosures. Drs. Gellibolian and Markaryan have shares in CellectGen, a for-profit organization focused on developing some of the point-of-care technologies proposed in this commentary. The work is funded by private investment capital. None of the other authors reported any disclosures. ",

year = "2022",

month = sep,

doi = "10.1016/j.adaj.2022.03.005",

language = "English",

volume = "153",

pages = "826--828",

number = "9",

}

TY - JOUR

T1 - Precision periodontics

T2 - Quantitative measures of disease progression

AU - Gellibolian, Robert

AU - Miller, Craig S.

AU - Markaryan, Adam N.

AU - Weltman, Robin L.

AU - Van Dyke, Thomas E.

AU - Ebersole, Jeffrey L.

N1 - Funding Information: Disclosures. Drs. Gellibolian and Markaryan have shares in CellectGen, a for-profit organization focused on developing some of the point-of-care technologies proposed in this commentary. The work is funded by private investment capital. None of the other authors reported any disclosures.

PY - 2022/9

Y1 - 2022/9

UR - https://www.scopus.com/pages/publications/85129489505

UR - https://www.scopus.com/pages/publications/85129489505#tab=citedBy

U2 - 10.1016/j.adaj.2022.03.005

DO - 10.1016/j.adaj.2022.03.005

M3 - Editorial

C2 - 35525683

AN - SCOPUS:85129489505

SN - 0002-8177

VL - 153

SP - 826

EP - 828

JO - Journal of the American Dental Association

JF - Journal of the American Dental Association

IS - 9

ER -

Precision periodontics: Quantitative measures of disease progression

Bibliographical note

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this